Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. (NASDAQ: MDXG) is a Florida-incorporated regenerative medicine and advanced wound care company that files regular reports and disclosures with the U.S. Securities and Exchange Commission. On this page, investors can review MiMedx SEC filings, including current reports on Form 8-K that detail quarterly earnings announcements, investor presentations, and shareholder meeting results, as well as other periodic reports available through EDGAR.
Recent Form 8-K filings show MiMedx reporting quarterly financial results and furnishing earnings press releases and slide presentations under Items 2.02 and 7.01. Another 8-K describes the outcomes of the company’s annual meeting of shareholders, including director elections, advisory votes on executive compensation, ratification of the independent registered public accounting firm, and approval of amendments to the equity and cash incentive plan. These documents provide insight into MiMedx’s financial condition, governance, and shareholder decisions.
For a fuller picture of MiMedx’s business, risks, and accounting policies, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible via the SEC’s EDGAR system. Those filings contain detailed discussions of the company’s advanced wound care and placental tissue–based product portfolio, risk factors, legal and regulatory matters, and management’s analysis of operations.
Stock Titan’s SEC filings page is designed to surface MiMedx filings as they are posted to EDGAR and to pair them with AI-generated summaries. These summaries can help explain complex sections of lengthy documents, highlight key items such as revenue trends, legal disclosures, or shareholder votes, and make it easier to locate information on topics like reimbursement risk, litigation with former employees, or regulatory interactions. Users can also review insider and governance-related disclosures, such as say-on-pay frequency decisions, as they appear in MiMedx’s filed materials.
MIMEDX GROUP, INC. General Counsel and Chief Administrative Officer William Frank Hulse IV reported a tax-related share disposition. On March 13, 2026, 20,245 shares of common stock were withheld at $4.38 per share to cover tax obligations on vesting of restricted stock. After this withholding, he directly holds 543,195 shares of MIMEDX common stock, indicating this was a routine compensation and tax event rather than an open-market trade.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported a routine tax-related share disposition. On March 13, 2026, 6,762 shares of common stock were withheld at $4.38 per share to cover tax obligations on vesting of restricted stock.
These shares were withheld by the company rather than sold in the open market. After this transaction, Maersk-Moller directly owned 329,450 shares of MiMedx common stock.
MIMEDX GROUP Chief Commercial Officer Kimberly Maersk-Moller reported compensation-related share activity. On this Form 4, 42,845 shares of common stock were acquired on March 10, 2026 through the vesting of performance stock units granted on March 13, 2023. Of these, 21,270 shares were withheld to cover tax obligations required by company policy, leaving her with 336,212 shares of common stock owned directly after the transactions.
MIMEDX GROUP General Counsel and CAO William Frank Hulse IV received common shares through the vesting of performance stock units at $4.50 per share. A portion of the vested shares was withheld to cover tax obligations, leaving him with 563,440 directly owned shares after these transactions.
MiMedx Group Chief Financial Officer Doug Rice reported equity compensation activity tied to performance stock units (PSUs). On the reported date, he acquired 243,000 shares of common stock at $4.50 per share upon vesting of PSUs covering the performance period from January 1, 2023 to December 31, 2025.
In connection with this vesting, 96,363 shares were disposed of at $4.50 per share to satisfy tax obligations, with shares withheld as required by company policy rather than sold on the open market. After these transactions, Rice directly held 412,315 shares of MiMedx common stock.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
MiMedx Group, Inc. Chief Executive Officer Joseph H. Capper reported equity awards consisting of stock options and restricted stock granted on March 4, 2026. He was awarded 310,574 stock options and 371,094 shares of common stock at a price of $0.00 per share.
The restricted stock grant vests fully on the third anniversary of the grant date, subject to his continued employment under a Restricted Stock Unit Agreement. The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, also subject to continued employment.
MiMedx Group Chief Financial Officer Doug Rice received new equity awards in the form of stock options and restricted stock. On March 4, 2026, he was granted 62,068 stock options at an exercise price of $0.00 per share and 74,163 shares of common stock as a restricted stock grant.
The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, contingent on his continued employment under the Nonqualified Stock Option Agreement. The restricted stock vests fully on the third anniversary of the grant date, also subject to continued employment under the Restricted Stock Unit Agreement.
Hulse William Frank IV reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. General Counsel and Chief Administrative Officer William Frank Hulse IV reported equity awards on Common Stock and Stock Options. These are classified as grants or awards rather than open‑market purchases or sales.
The filing shows an award of 74,987 shares of Common Stock at a price per share of $0.0000, bringing his directly held Common Stock to 488,536 shares. According to the footnotes, this represents restricted stock that vests fully on the third anniversary of the grant, subject to his continued employment under the Restricted Stock Unit Agreement.
He also received Stock Options covering 62,758 shares at a price per share of $0.0000, increasing his directly held options to 171,190. The options vest 25% on each anniversary of the grant date, conditioned on his continued employment as described in the Nonqualified Stock Option Agreement.
MIMEDX GROUP, INC. Chief Operating Officer Ricci S. Whitlow reported equity awards on March 4, 2026. She acquired 62,068 stock options and 74,163 shares of restricted common stock at a price of $0.00 per share as compensation grants.
The restricted stock vests fully on the third anniversary of the grant, subject to continued employment. The options vest in four equal annual installments, each 25% on the grant-date anniversaries, also conditioned on continued employment. Following these grants, she directly holds 169,309 stock options and 462,825 common shares.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported equity awards on March 4, 2026. She was granted 62,068 stock options at an exercise price of $0.00 per share, increasing her directly held options to 137,862 following the grant.
She also received a grant of 74,163 shares of common stock at $0.00 per share, raising her directly held common shares to 314,637. Footnotes state the common stock grant consists of restricted stock that vests fully on the third anniversary of the grant, and that the options vest in 25% increments on each anniversary of the grant date, in both cases conditioned on continued employment.